Open an account

United Therapeutics

UTHR · NASDAQ

$553.88+$10.73 (+1.98%)TodayMarket closed ·
Prev close $543.15

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.

Employees
1,400
Headquarters
Silver Spring, Maryland
Listed
Jun 17, 1999
Sector
Health Care
Industry
Biotechnology
Website
unither.com

UTHR key statistics

Market cap
23.75B
Price-earnings ratio
19.44
Dividend yield
—
Average volume
944.43K
Volume
443.55K
Open price
$547.14
High today
$564.97
Low today
$545.58
52 Week high
$609.35
52 Week low
$409.07

United Therapeutics (UTHR) at a glance

United Therapeutics (UTHR) last traded at $553.88, with a market cap of 23.75B and a price-to-earnings ratio of 19.44.

Today the stock has traded between $545.58 and $564.97. The current price is 1.5% above the day's low and 2.0% below its high.

Volume so far is 443.55K shares, below the average of 944.43K shares a day.

Over the past year United Therapeutics has ranged from $409.07 to $609.35, and now sits 72% of the way up that range.

United Therapeutics met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q2 FY26 it reported $7.27 per share against an estimate of $6.97.

The average analyst price target is $648.03, 17.0% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

77%of 13 analyst ratings say Buy
  • Buy76.9%
  • Hold15.4%
  • Sell7.7%
Price target · 18 analystsAvg $648.03
Low
$324.21
Now
$553.88
High
$764.40

UTHR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 4.7% on average.

  1. Q3 FY24: reported $6.39 per share against an estimate of $6.55
  2. Q4 FY24: reported $6.19 per share against an estimate of $6.44
  3. Q1 FY25: reported $6.63 per share against an estimate of $6.66
  4. Q2 FY25: reported $6.41 per share against an estimate of $7.08
  5. Q3 FY25: reported $7.16 per share against an estimate of $7.33
  6. Q4 FY25: reported $7.70 per share against an estimate of $7.33
  7. Q1 FY26: reported $5.82 per share against an estimate of $7.01
  8. Q2 FY26: reported $7.27 per share against an estimate of $6.97

UTHR news

  • Press releaseBusiness Wire

    United Therapeutics Expands Organ Manufacturing Capabilities with Opening of Third Designated Pathogen-Free Xenograft Production Facility

  • Press releaseBusiness Wire

    United Therapeutics Announces FDA Clearance to Proceed with SUMMIT Clinical Trial for Treprostinil SMI in PH-COPD

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow, Nasdaq Futures Gain Even as September Inflation Report Comes In Hotter Than Expected— ASML, AZZ, GME in Focus (UPDATED)

  • Neeraj Jain

    Liquidia Settles Bitter Fight With United Therapeutics

  • Press releaseBusiness Wire

    United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

  • Henry Khederian

    United Therapeutics Stock Rises Following Federal Court Patent Victory Over Liquidia

  • Mohd Haider

    Why is Liquidia (LQDA) Stock Trending After Hours?

  • Press releaseBusiness Wire

    United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

Similar companies

Companies in the same industry as United Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.